Oncology Highlights - October 2019
Niraparib increases PFS in advanced ovarian cancer and ramucirumab and erlotinib increase PFS in metastatic NSCLC
Oncology Highlights - September 2019
Tumor mutational burden not associated with pembrolizumab efficacy in NSCLC and insight in a new safe and potent anti-CD19 CAR T cell therapy
Oncology Highlights - August 2019
Selection of TP53 missense mutation driven by a dominant-negative effect, neutral genetic drift as cause of long-term cancer evolution, infusions of humanized anti-CD19 and anti-BCMA CAR T cells are feasible
Oncology Highlights - July 2019
Soft drinks and fruit juice associated with increased risk of cancer, enhanced CAR-T cell efficacy in solid tumors, Prolonged PFS in solid tumors with NEO-PV-01
Oncology Highlights - June 2019
Astrocytes play role immunosuppression, TILs related to spatial distribution, FDA and EMA approvals, ASCO guidelines
All eyes on ESMO 2019
All eyes on ESMO 2019 This year's annual European Society for Medical Oncology (ESMO) 2019 Congress took place from 27-30 September. Researchers, clinicians, cancer nurses, industry partners and patient advocates from all over...
AACR 2019 - Forward and reverse translational era
When most people think of the city of Atlanta (Georgia, USA), they think about Coca Cola, the Olympic stadium, or perhaps the Delta Airlines hub. But last week (29 March - 3 April 2019), this southern city was home to more than...
The growing challenge of handling multistream data capture in clinical trials - ACDM 2019
This year's annual conference of the Association for Clinical Data Management (ACDM) took place in Amsterdam. During a two-day event, the emphasis was on the growing challenges of multistream data capture in clinical trials, wi...
SMS-oncology sets out to improve patient recruitment for clinical trials
Drug development crucially relies on accurately designed and well recruiting clinical trials. However, low accrual rates of clinical trials and unmet recruitment targets have been global attention points for many years. A 70-80...
EMA & FDA Anti-cancer Drugs Recommendations for Approval in 2018
In 2018, EMA and FDA made a total of 44 positive recommendations for anti-cancer medicines to receive marketing approval.